Global Antiviral Combination Therapies Market
Global Antiviral Combination Therapies Market

Antiviral Combination Therapies Comprehensive Study by Type (Branded, Generic), Route of Administration (Oral, Intravenous), Indication (HIV, Hepatitis, Others), Drug Combination (NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, Others) Players and Region - Global Market Outlook to 2026

Antiviral Combination Therapies Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 240 Pages 216 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antiviral Combination Therapies Market?

During the assessment period, the demand for antiviral combination therapies is expected to grow at a rapid pace. In order to innovate in combination therapy trials, medical institutes are increasing their efforts to partner with hospitals. Antiviral drugs combined with antibiotics have been found to have promising potential in reducing coronavirus symptoms in patients. Traditional Chinese medicine (TCM) combined with antiviral drugs for the treatment of chronic hepatitis B is one of the latest therapy avenues being investigated by healthcare companies (CHB). For red blood cells, the Chinese antiviral decoction YinQiSanHuang with entecavir is becoming more common.

The market study is being classified by Type (Branded and Generic) and major geographies with country level break-up.

Celltrion, Inc. (South Korea), GlaxoSmithKline plc (United Kingdom), Gilead Sciences, Inc. (United States), AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), Janssen Global Services (United States), Cipla, Inc. (India), Mylan N.V. (United States), Merck & Co., Inc. (United States) and F. Hoffmann-La Roche Ltd. (Switzerland) are some of the key players profiled in the study.

The global Antiviral Combination Therapies market is highly competitive. To survive in the competitive market, key players adopted advanced healthcare technology for improved healthcare services. Furthermore, in order to retain market share and diversify its product portfolio, major players often adopt strategies such as mergers, acquisitions, and new product launches. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antiviral Combination Therapies market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Antiviral Combination Therapies market by Type, Application and Region.

On the basis of geography, the market of Antiviral Combination Therapies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growth in Spending on Research & Development by Market Players for the Development of Effective Antiviral Combination Therapies for the Treatment of a Range of Viral Diseases

Market Trend
  • Rising Ability of the Combination Therapy to Control the Antibiotic Resistance

Restraints
  • Stringent Regulatory Norms regarding Therapies

Opportunities
  • Increase in Focus on Drug Repurposing and Vaccine Development for the Treatment of COVID-19
  • Rising Number of Product Approvals for Combination Therapy

Challenges
  • High Cost of Antiviral Drug Treatment


In August 2020, Janssen Global Services entered into an agreement with the U.S. Government for the large-scale development and manufacturing of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the U.S., following the approval of Emergency Use Authorization by the U.S. Food and Drug Administration (FDA), and In May 2020, Gilead received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Veklury (remdesivir), for the treatment of COVID-19 in Japanese patients


Key Target Audience
Research Organisations, Government & Regulatory Bodies, Health Care Sector, Potential Investors and Downstream Vendors

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Branded
  • Generic
By Route of Administration
  • Oral
  • Intravenous

By Indication
  • HIV
  • Hepatitis
  • Others

By Drug Combination
  • NRTI/NNRTI
  • Integrase Inhibitor/NRTI
  • NRTI
  • NRTI/Protease Inhibitor
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Spending on Research & Development by Market Players for the Development of Effective Antiviral Combination Therapies for the Treatment of a Range of Viral Diseases
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Antiviral Drug Treatment
    • 3.4. Market Trends
      • 3.4.1. Rising Ability of the Combination Therapy to Control the Antibiotic Resistance
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiviral Combination Therapies, by Type, Route of Administration, Indication, Drug Combination and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antiviral Combination Therapies (Value)
      • 5.2.1. Global Antiviral Combination Therapies by: Type (Value)
        • 5.2.1.1. Branded
        • 5.2.1.2. Generic
      • 5.2.2. Global Antiviral Combination Therapies by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
      • 5.2.3. Global Antiviral Combination Therapies by: Indication (Value)
        • 5.2.3.1. HIV
        • 5.2.3.2. Hepatitis
        • 5.2.3.3. Others
      • 5.2.4. Global Antiviral Combination Therapies by: Drug Combination (Value)
        • 5.2.4.1. NRTI/NNRTI
        • 5.2.4.2. Integrase Inhibitor/NRTI
        • 5.2.4.3. NRTI
        • 5.2.4.4. NRTI/Protease Inhibitor
        • 5.2.4.5. Others
      • 5.2.5. Global Antiviral Combination Therapies Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Antiviral Combination Therapies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Celltrion, Inc. (South Korea)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gilead Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AbbVie, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Janssen Global Services (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla, Inc. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mylan N.V. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antiviral Combination Therapies Sale, by Type, Route of Administration, Indication, Drug Combination and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antiviral Combination Therapies (Value)
      • 7.2.1. Global Antiviral Combination Therapies by: Type (Value)
        • 7.2.1.1. Branded
        • 7.2.1.2. Generic
      • 7.2.2. Global Antiviral Combination Therapies by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
      • 7.2.3. Global Antiviral Combination Therapies by: Indication (Value)
        • 7.2.3.1. HIV
        • 7.2.3.2. Hepatitis
        • 7.2.3.3. Others
      • 7.2.4. Global Antiviral Combination Therapies by: Drug Combination (Value)
        • 7.2.4.1. NRTI/NNRTI
        • 7.2.4.2. Integrase Inhibitor/NRTI
        • 7.2.4.3. NRTI
        • 7.2.4.4. NRTI/Protease Inhibitor
        • 7.2.4.5. Others
      • 7.2.5. Global Antiviral Combination Therapies Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiviral Combination Therapies: by Type(USD Million)
  • Table 2. Antiviral Combination Therapies Branded , by Region USD Million (2015-2020)
  • Table 3. Antiviral Combination Therapies Generic , by Region USD Million (2015-2020)
  • Table 4. Antiviral Combination Therapies: by Route of Administration(USD Million)
  • Table 5. Antiviral Combination Therapies Oral , by Region USD Million (2015-2020)
  • Table 6. Antiviral Combination Therapies Intravenous , by Region USD Million (2015-2020)
  • Table 7. Antiviral Combination Therapies: by Indication(USD Million)
  • Table 8. Antiviral Combination Therapies HIV , by Region USD Million (2015-2020)
  • Table 9. Antiviral Combination Therapies Hepatitis , by Region USD Million (2015-2020)
  • Table 10. Antiviral Combination Therapies Others , by Region USD Million (2015-2020)
  • Table 11. Antiviral Combination Therapies: by Drug Combination(USD Million)
  • Table 12. Antiviral Combination Therapies NRTI/NNRTI , by Region USD Million (2015-2020)
  • Table 13. Antiviral Combination Therapies Integrase Inhibitor/NRTI , by Region USD Million (2015-2020)
  • Table 14. Antiviral Combination Therapies NRTI , by Region USD Million (2015-2020)
  • Table 15. Antiviral Combination Therapies NRTI/Protease Inhibitor , by Region USD Million (2015-2020)
  • Table 16. Antiviral Combination Therapies Others , by Region USD Million (2015-2020)
  • Table 17. South America Antiviral Combination Therapies, by Country USD Million (2015-2020)
  • Table 18. South America Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 19. South America Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 21. South America Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 22. Brazil Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 23. Brazil Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 24. Brazil Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 25. Brazil Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 26. Argentina Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 27. Argentina Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 28. Argentina Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 29. Argentina Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 30. Rest of South America Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 32. Rest of South America Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 33. Rest of South America Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 34. Asia Pacific Antiviral Combination Therapies, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 38. Asia Pacific Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 39. China Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 40. China Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 41. China Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 42. China Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 43. Japan Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 44. Japan Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 45. Japan Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 46. Japan Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 47. India Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 48. India Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 49. India Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 50. India Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 51. South Korea Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 52. South Korea Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 53. South Korea Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 54. South Korea Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 55. Taiwan Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 56. Taiwan Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 57. Taiwan Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 58. Taiwan Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 59. Australia Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 60. Australia Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 61. Australia Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 62. Australia Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 67. Europe Antiviral Combination Therapies, by Country USD Million (2015-2020)
  • Table 68. Europe Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 69. Europe Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 70. Europe Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 71. Europe Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 72. Germany Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 73. Germany Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 74. Germany Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 75. Germany Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 76. France Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 77. France Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 78. France Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 79. France Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 80. Italy Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 81. Italy Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 82. Italy Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 83. Italy Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 84. United Kingdom Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 86. United Kingdom Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 87. United Kingdom Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 88. Netherlands Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 89. Netherlands Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 90. Netherlands Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 91. Netherlands Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 92. Rest of Europe Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 94. Rest of Europe Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 95. Rest of Europe Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 96. MEA Antiviral Combination Therapies, by Country USD Million (2015-2020)
  • Table 97. MEA Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 98. MEA Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 99. MEA Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 100. MEA Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 101. Middle East Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 102. Middle East Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 103. Middle East Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 104. Middle East Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 105. Africa Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 106. Africa Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 107. Africa Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 108. Africa Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 109. North America Antiviral Combination Therapies, by Country USD Million (2015-2020)
  • Table 110. North America Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 111. North America Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 112. North America Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 113. North America Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 114. United States Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 115. United States Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 116. United States Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 117. United States Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 118. Canada Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 119. Canada Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 120. Canada Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 121. Canada Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 122. Mexico Antiviral Combination Therapies, by Type USD Million (2015-2020)
  • Table 123. Mexico Antiviral Combination Therapies, by Route of Administration USD Million (2015-2020)
  • Table 124. Mexico Antiviral Combination Therapies, by Indication USD Million (2015-2020)
  • Table 125. Mexico Antiviral Combination Therapies, by Drug Combination USD Million (2015-2020)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Antiviral Combination Therapies: by Type(USD Million)
  • Table 137. Antiviral Combination Therapies Branded , by Region USD Million (2021-2026)
  • Table 138. Antiviral Combination Therapies Generic , by Region USD Million (2021-2026)
  • Table 139. Antiviral Combination Therapies: by Route of Administration(USD Million)
  • Table 140. Antiviral Combination Therapies Oral , by Region USD Million (2021-2026)
  • Table 141. Antiviral Combination Therapies Intravenous , by Region USD Million (2021-2026)
  • Table 142. Antiviral Combination Therapies: by Indication(USD Million)
  • Table 143. Antiviral Combination Therapies HIV , by Region USD Million (2021-2026)
  • Table 144. Antiviral Combination Therapies Hepatitis , by Region USD Million (2021-2026)
  • Table 145. Antiviral Combination Therapies Others , by Region USD Million (2021-2026)
  • Table 146. Antiviral Combination Therapies: by Drug Combination(USD Million)
  • Table 147. Antiviral Combination Therapies NRTI/NNRTI , by Region USD Million (2021-2026)
  • Table 148. Antiviral Combination Therapies Integrase Inhibitor/NRTI , by Region USD Million (2021-2026)
  • Table 149. Antiviral Combination Therapies NRTI , by Region USD Million (2021-2026)
  • Table 150. Antiviral Combination Therapies NRTI/Protease Inhibitor , by Region USD Million (2021-2026)
  • Table 151. Antiviral Combination Therapies Others , by Region USD Million (2021-2026)
  • Table 152. South America Antiviral Combination Therapies, by Country USD Million (2021-2026)
  • Table 153. South America Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 154. South America Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 155. South America Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 156. South America Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 157. Brazil Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 158. Brazil Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 159. Brazil Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 160. Brazil Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 161. Argentina Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 162. Argentina Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 163. Argentina Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 164. Argentina Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 165. Rest of South America Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 166. Rest of South America Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 167. Rest of South America Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 168. Rest of South America Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 169. Asia Pacific Antiviral Combination Therapies, by Country USD Million (2021-2026)
  • Table 170. Asia Pacific Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 171. Asia Pacific Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 172. Asia Pacific Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 173. Asia Pacific Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 174. China Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 175. China Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 176. China Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 177. China Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 178. Japan Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 179. Japan Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 180. Japan Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 181. Japan Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 182. India Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 183. India Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 184. India Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 185. India Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 186. South Korea Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 187. South Korea Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 188. South Korea Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 189. South Korea Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 190. Taiwan Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 191. Taiwan Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 192. Taiwan Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 193. Taiwan Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 194. Australia Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 195. Australia Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 196. Australia Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 197. Australia Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 202. Europe Antiviral Combination Therapies, by Country USD Million (2021-2026)
  • Table 203. Europe Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 204. Europe Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 205. Europe Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 206. Europe Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 207. Germany Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 208. Germany Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 209. Germany Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 210. Germany Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 211. France Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 212. France Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 213. France Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 214. France Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 215. Italy Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 216. Italy Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 217. Italy Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 218. Italy Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 219. United Kingdom Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 220. United Kingdom Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 221. United Kingdom Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 222. United Kingdom Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 223. Netherlands Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 224. Netherlands Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 225. Netherlands Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 226. Netherlands Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 227. Rest of Europe Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 228. Rest of Europe Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 229. Rest of Europe Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 230. Rest of Europe Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 231. MEA Antiviral Combination Therapies, by Country USD Million (2021-2026)
  • Table 232. MEA Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 233. MEA Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 234. MEA Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 235. MEA Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 236. Middle East Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 237. Middle East Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 238. Middle East Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 239. Middle East Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 240. Africa Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 241. Africa Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 242. Africa Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 243. Africa Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 244. North America Antiviral Combination Therapies, by Country USD Million (2021-2026)
  • Table 245. North America Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 246. North America Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 247. North America Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 248. North America Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 249. United States Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 250. United States Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 251. United States Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 252. United States Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 253. Canada Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 254. Canada Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 255. Canada Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 256. Canada Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 257. Mexico Antiviral Combination Therapies, by Type USD Million (2021-2026)
  • Table 258. Mexico Antiviral Combination Therapies, by Route of Administration USD Million (2021-2026)
  • Table 259. Mexico Antiviral Combination Therapies, by Indication USD Million (2021-2026)
  • Table 260. Mexico Antiviral Combination Therapies, by Drug Combination USD Million (2021-2026)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiviral Combination Therapies: by Type USD Million (2015-2020)
  • Figure 5. Global Antiviral Combination Therapies: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Antiviral Combination Therapies: by Indication USD Million (2015-2020)
  • Figure 7. Global Antiviral Combination Therapies: by Drug Combination USD Million (2015-2020)
  • Figure 8. South America Antiviral Combination Therapies Share (%), by Country
  • Figure 9. Asia Pacific Antiviral Combination Therapies Share (%), by Country
  • Figure 10. Europe Antiviral Combination Therapies Share (%), by Country
  • Figure 11. MEA Antiviral Combination Therapies Share (%), by Country
  • Figure 12. North America Antiviral Combination Therapies Share (%), by Country
  • Figure 13. Global Antiviral Combination Therapies share by Players 2020 (%)
  • Figure 14. Global Antiviral Combination Therapies share by Players (Top 3) 2020(%)
  • Figure 15. Global Antiviral Combination Therapies share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Celltrion, Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 18. Celltrion, Inc. (South Korea) Revenue: by Geography 2020
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Gilead Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. AbbVie, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 27. Janssen Global Services (United States) Revenue, Net Income and Gross profit
  • Figure 28. Janssen Global Services (United States) Revenue: by Geography 2020
  • Figure 29. Cipla, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla, Inc. (India) Revenue: by Geography 2020
  • Figure 31. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 33. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 35. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 37. Global Antiviral Combination Therapies: by Type USD Million (2021-2026)
  • Figure 38. Global Antiviral Combination Therapies: by Route of Administration USD Million (2021-2026)
  • Figure 39. Global Antiviral Combination Therapies: by Indication USD Million (2021-2026)
  • Figure 40. Global Antiviral Combination Therapies: by Drug Combination USD Million (2021-2026)
  • Figure 41. South America Antiviral Combination Therapies Share (%), by Country
  • Figure 42. Asia Pacific Antiviral Combination Therapies Share (%), by Country
  • Figure 43. Europe Antiviral Combination Therapies Share (%), by Country
  • Figure 44. MEA Antiviral Combination Therapies Share (%), by Country
  • Figure 45. North America Antiviral Combination Therapies Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Celltrion, Inc. (South Korea)
  • GlaxoSmithKline plc (United Kingdom)
  • Gilead Sciences, Inc. (United States)
  • AbbVie, Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Janssen Global Services (United States)
  • Cipla, Inc. (India)
  • Mylan N.V. (United States)
  • Merck & Co., Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) ...
Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) ...
$ 3800
Acute Agitation and Aggression Treatment Comprehensive Study by Therapy (Chemotherapy, Cognitive Behavioural Therapy (CBT), Others), Route of Administration (Oral, Sublingual, Intramuscular, Others),...
Acute Agitation and Aggression Treatment Comprehensive Study by Therapy (Chemotherapy, Cognitive Behavioural Therapy (CBT), Others), Route of Administration (Oral, Sublingual, Intramuscular, Others),...
$ 3800
Dyslexia Treatment Comprehensive Study by Type (Phonological Dyslexia, Surface Dyslexia), Treatment (Drug Class, Tools, Educational Techniques), End-users (Hospitals, Home Care, Others), Distribution...
Dyslexia Treatment Comprehensive Study by Type (Phonological Dyslexia, Surface Dyslexia), Treatment (Drug Class, Tools, Educational Techniques), End-users (Hospitals, Home Care, Others), Distribution...
$ 3800
Deep Vein Thrombosis Treatment Comprehensive Study by Type (Medication, Devices, Surgery), Application (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, Other), End Users (Hospitals, Ho...
Deep Vein Thrombosis Treatment Comprehensive Study by Type (Medication, Devices, Surgery), Application (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, Other), End Users (Hospitals, Ho...
$ 3800
Veterinary Artificial Insemination Comprehensive Study by Type (Equipment, Reagents and Kits, Other), Animal (Ruminants, Equine, Canine and Feline, Other), Technique (Intrauterine Tub peritoneal Ins...
Veterinary Artificial Insemination Comprehensive Study by Type (Equipment, Reagents and Kits, Other), Animal (Ruminants, Equine, Canine and Feline, Other), Technique (Intrauterine Tub peritoneal Ins...
$ 3800
Dent Disease Treatment Comprehensive Study by Drug Type (Calcium Phosphate, Cysteine, Angiotensin-Converting Enzyme (ACE) Inhibitor, Angiotensin Receptor Blockers, Uric Acid, Calcium Oxalate, Thiazid...
Dent Disease Treatment Comprehensive Study by Drug Type (Calcium Phosphate, Cysteine, Angiotensin-Converting Enzyme (ACE) Inhibitor, Angiotensin Receptor Blockers, Uric Acid, Calcium Oxalate, Thiazid...
$ 3800